Cargando…

Do GLP-1–Based Therapies Increase Cancer Risk?

Detalles Bibliográficos
Autores principales: Nauck, Michael A., Friedrich, Nele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920789/
https://www.ncbi.nlm.nih.gov/pubmed/23882053
http://dx.doi.org/10.2337/dcS13-2004
_version_ 1782303227584184320
author Nauck, Michael A.
Friedrich, Nele
author_facet Nauck, Michael A.
Friedrich, Nele
author_sort Nauck, Michael A.
collection PubMed
description
format Online
Article
Text
id pubmed-3920789
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-39207892014-08-01 Do GLP-1–Based Therapies Increase Cancer Risk? Nauck, Michael A. Friedrich, Nele Diabetes Care Diabetes and Cancer American Diabetes Association 2013-08 2013-07-17 /pmc/articles/PMC3920789/ /pubmed/23882053 http://dx.doi.org/10.2337/dcS13-2004 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Diabetes and Cancer
Nauck, Michael A.
Friedrich, Nele
Do GLP-1–Based Therapies Increase Cancer Risk?
title Do GLP-1–Based Therapies Increase Cancer Risk?
title_full Do GLP-1–Based Therapies Increase Cancer Risk?
title_fullStr Do GLP-1–Based Therapies Increase Cancer Risk?
title_full_unstemmed Do GLP-1–Based Therapies Increase Cancer Risk?
title_short Do GLP-1–Based Therapies Increase Cancer Risk?
title_sort do glp-1–based therapies increase cancer risk?
topic Diabetes and Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920789/
https://www.ncbi.nlm.nih.gov/pubmed/23882053
http://dx.doi.org/10.2337/dcS13-2004
work_keys_str_mv AT nauckmichaela doglp1basedtherapiesincreasecancerrisk
AT friedrichnele doglp1basedtherapiesincreasecancerrisk